Jeitner TM, Azcona JA, Ables GP, Cooke D, Horowitz MC, Singh P, Kelly JM, Cooper AJL.  2023.  Cystine rather than cysteine is the preferred substrate for β-elimination by cystathionine γ-lyase: implications for dietary methionine restriction.. Geroscience.

Jeitner TM, Pinto JT, Cooper AJL.  2018.  Cystamine and cysteamine as inhibitors of transglutaminase activity .. Biosci Rep. 38(5)

Hariharan VA, Denton TT, Paraszcszak S, McEvoy K, Jeitner TM, Krasnikov BF, Cooper AJL.  2017.  The Enzymology of 2-Hydroxyglutarate, 2-Hydroxyglutaramate and 2-Hydroxysuccinamate and Their Relationship to Oncometabolites.. Biology (Basel). 6(2)

Cooper AJL, Jeitner TM.  2016.  Central Role of Glutamate Metabolism in the Maintenance of Nitrogen Homeostasis in Normal and Hyperammonemic Brain.. Biomolecules. 6(2)

Jeitner TM, Kristoferson E, Azcona JA, Pinto JT, Stalnecker C, Erickson JW, Kung HF, Li J, Ploessl K, Cooper AJL.  2016.  Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias.. J Fluor Chem. 192(A):58-67.

Jeitner TM, Battaile K, Cooper AJL.  2015.  Critical Evaluation of the Changes in Glutamine Synthetase Activity in Models of Cerebral Stroke.. Neurochem Res. 40(12):2544-56.

Jeitner TM, Cooper AJL.  2014.  Inhibition of human glutamine synthetase by L-methionine-S,R-sulfoximine-relevance to the treatment of neurological diseases.. Metab Brain Dis. 29(4):983-9.

Jeitner TM, Battaile K, Cooper AJL.  2013.  γ-Glutamylamines and neurodegenerative diseases.. Amino Acids. 44(1):129-42.

Pinto JT, Khomenko T, Szabo S, McLaren GD, Denton TT, Krasnikov BF, Jeitner TM, Cooper AJL.  2009.  Measurement of sulfur-containing compounds involved in the metabolism and transport of cysteamine and cystamine. Regional differences in cerebral metabolism.. J Chromatogr B Analyt Technol Biomed Life Sci. 877(28):3434-41.

Jeitner TM, Pinto JT, Krasnikov BF, Horswill M, Cooper AJL.  2009.  Transglutaminases and neurodegeneration.. J Neurochem. 109 Suppl 1:160-6.

Jeitner TM, Matson WR, Folk JE, Blass JP, Cooper AJL.  2008.  Increased levels of gamma-glutamylamines in Huntington disease CSF.. J Neurochem. 106(1):37-44.

Jeitner TM, E Delikatny J, Ahlqvist J, Capper H, Cooper AJL.  2005.  Mechanism for the inhibition of transglutaminase 2 by cystamine.. Biochem Pharmacol. 69(6):961-70.

Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJL.  2005.  Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease.. J Neurochem. 94(4):1087-101.

Cooper AJL, Krasnikov BF, Okuno E, Jeitner TM.  2003.  L-alanine-glyoxylate aminotransferase II of rat kidney and liver mitochondria possesses cysteine S-conjugate beta-lyase activity: a contributing factor to the nephrotoxicity/hepatotoxicity of halogenated alkenes? Biochem J. 376(Pt 1):169-78.

Cooper AJL, Jeitner TM, Gentile V, Blass JP.  2002.  Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases? Neurochem Int. 40(1):53-67.

Cooper AJL, Jeitner TM, Blass JP.  2002.  The role of transglutaminases in neurodegenerative diseases: overview.. Neurochem Int. 40(1):1-5.

Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJL, Ratan RR, M Beal F et al..  2002.  Therapeutic effects of cystamine in a murine model of Huntington's disease.. J Neurosci. 22(20):8942-50.